Polaryx Therapeutics, Inc. (PLYX) stock
PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.60−0.07 (-4.19%)
Close on Nov 17, 2026Market cap $79.75MP/E –Yield –
Polaryx Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Polaryx Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $4.41M. For fiscal 2025 it was $6.27M, up 122.9% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.27M | +122.9% |
| FY2024 | Dec 31, 2024 | $2.81M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.45M | +376.8% |
| Q2 FY2026 | Jun 30, 2026 | $719.00K | +51.1% |
| Q1 FY2026 | Mar 31, 2026 | $679.00K | -85.6% |
| Q4 FY2025 | Dec 31, 2025 | $560.00K | – |
| Q3 FY2025 | Sep 30, 2025 | $514.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $476.00K | – |
| Q1 FY2025 | Mar 31, 2025 | $4.72M | – |
See a number that looks wrong?